Senseonics Eversense 365 Delivers 93.8% Wear Time, CE Mark Approved for Europe
Senseonics reported real-world data from 5,059 Eversense 365 sensors showing 93.8% transmitter wear time, a 7.14% Glucose Management Indicator and 66% Time in Range sustained over the one-year cycle, with users aged 65+ achieving a 6.99% GMI, over 70% TIR and 95% wear time. The company secured CE Mark approval and plans launches in Germany, Italy, Spain and Sweden.
1. Real-World Evidence for Eversense 365
Senseonics reported data from 5,059 real-world sensors showing a 93.8% transmitter wear time, a mean Glucose Management Indicator of 7.14% and a 66% Time in Range sustained over both six-month periods of the one-year cycle. Over 75% of users met hypoglycemic targets, with patients aged 65 and older achieving a 6.99% GMI, over 70% Time in Range and 95% wear time.
2. Twiist Automated Insulin Delivery Integration
Early results from approximately 120 patients using the twiist Automated Insulin Delivery system with Eversense 365 demonstrated a mean GMI of 6.79%, a 77% Time in Range and just 2.7% time in hypoglycemia, meeting international consensus targets for glycemic control.
3. CE Mark Approval and European Expansion
Senseonics secured CE Mark approval for Eversense 365 and plans to launch the year-long continuous glucose monitor in Germany, Italy, Spain and Sweden in the coming months, opening new markets for its sensor technology.